Eligible beneficiaries can get some GLP-1 drugs cheaper, but BMI and medical conditions decide who qualifies, and it runs apart from Part D.
Recap by typeshit. Post by X on X.
An explainer on talking to a provider about whether Wegovy fits you, plus a reminder that insurance may not pay for it.
Khunti shares real-world data on over a million UK adults using telehealth for obesity care, where 90% started on tirzepatide before a major price hike changed prescribing.
Polskie Radio reports a Wegovy price cut in China, coming soon after the drug's approval there. Tap through for the details.
Novo Nordisk is cutting what Wegovy costs in China, Polskie Radio reports. Tap through for the size of the cut and when it takes effect.
A Medscape opinion roundup on food cravings, the long-term staying power of bariatric surgery, and how tirzepatide is starting to compete with it.
28:35
An animated look at how many people are taking retatrutide before any approval, and what that means for the gray market.
Loading…